Skip to main content

Articles

Payers' Guide, FDA Approvals

Revlimid (Lenalidomide) Receives New Indication for Multiple Myeloma as Maintenance Therapy After Transplantation

Payers' Guide, FDA Approvals

Rubraca (Rucaparib) Second PARP Inhibitor Approved for Patients with Advanced, BRCA-Positive Ovarian Cancer

Payers' Guide, FDA Approvals

Soliqua 100/33 (Insulin Glargine plus Lixisenatide) Receives FDA Approval for Adults with Type 2 Diabetes

Payers' Guide, FDA Approvals

Sustol (Granisetron) First Extended-Release 5-HT3 Receptor Antagonist Approved for the Prevention of Acute and Delayed CINV

Payers' Guide, FDA Approvals

Xeljanz XR (Tofacitinib) First Once-Daily Oral JAK Inhibitor Approved for Patients with Rheumatoid Arthritis

FDA Approvals, Payers' Guide

Innovation Continues to Drive Drug Development, Even as FDA Approvals Drop in 2016

The Dream of Value-Based Care

David B. Nash, MD, MBA

Practice Management

Sociodemographic Determinants of Out-of-Pocket Expenditures for Patients Using Prescription Drugs for Rheumatoid Arthritis

Kumar Mukherjee, PhD; Khalid M. Kamal, PhD

Stakeholder Perspective

Understanding Patients’ Demographics Is Key to Improving Clinical and Economic Healthcare Outcomes

F. Randy Vogenberg, RPh, PhD

Pharmaceutical Patent Litigation and the Emerging Biosimilars: A Conversation with Kevin M. Nelson, JD

Stanton R. Mehr

Practice Management

Biologic Disease-Modifying Antirheumatic Drugs in a National, Privately Insured Population: Utilization, Expenditures, and Price Trends

Christopher B. Atzinger, MS, PhD candidate; Jeff J. Guo, BPharm, PhD

Stakeholder Perspective

Rheumatoid Arthritis, Biologic Drugs, and Associated Cost

Byron C. Scott, MD, MBA

Page 94 of 244
Results 931 - 940 of 2434